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Abstract: Snake venoms are complex toxin mixtures. Viperidae and Crotalidae venoms, 
which are hemotoxic, are responsible for most of the envenomations around the world. 
Administration of antivenins aimed at the neutralization of toxins in humans is prone to 
potential risks. Neutralization of snake venom toxins has been achieved through different 
approaches: plant extracts have been utilized in etnomedicine. Direct electric current from 
low  voltage  showed  neutralizing  properties  against  venom  phospholipase  A2  and 
metalloproteases.  This  mini-review  summarizes  new  achievements  in  venom  key 
component inhibition. A deeper knowledge of alternative ways to inhibit venom toxins 
may provide supplemental treatments to serum therapy.  
Keywords:  antivenins;  direct  electric  current;  etnomedicine;  metalloprotease; 
phospholipase A2; phosphodiesterase; snake venom 
 
1. Geographic Distribution of Venomous Snake Families 
Snake  venoms  are  complex  mixtures  of  biologically  active  proteins,  peptides,  metal  ions  and 
organic  compounds,  which  have  evolved  to  favor  the  survival  of  the  snake  in  its  particular 
environment [1]. There are more than 600 known species of venomous snakes—about a quarter of all 
snake  species—classified  into  several  families:  Elapidae,  Viperidae,  Crotalidae,  Hydrophidae, 
Atractaspididae and Colubridae [2]. Their venoms are classified as hemotoxic if they primarily affect 
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the cardiovascular system, or neurotoxic if they affect the central nervous system (CNS) and muscular 
system [3].  
In  Central  and  South  America,  the  United  States  (USA),  Australia,  India  and  Africa,  about  
2.5 million people are bitten by snakes annually and more than 100,000 fatally [4–8]. Most morbidity 
and mortality occurs in rural areas in the tropics [9], with farmers, hunter gatherers, herdsmen and 
children being the major groups at risk. In the USA, every state but Maine, Alaska and Hawaii is home 
to at least one of 20 domestic poisonous snake species [10–12]. In the USA, 99 percent of snakebites 
result from envenomation with snakes of the family Viperidae or family Crotalidae (which includes 
rattlesnakes, copperheads and water moccasins) [11]. Snakes of the families Viperidae and Elapidae 
are also responsible for the high incidence of snake bites in West Africa, the Indian subcontinent, 
South-East Asia, New Guinea and Latin America [5,10]. Due to their widespread distribution and 
relatively  potent  venom,  the  fatalities  caused  by  rattlesnakes  are  the  most  diffused  and  best 
documented.  Pit  vipers  of  the  genus  Bothrops  are  responsible  for  the  majority  of  fatalities  from 
snakebites in Latin America [11]. The Puff Adder, a common name of snake species of the genus Bitis, 
is considered Africa‘s most dangerous snake as it is responsible for more fatalities than any other 
snake in Africa. In Europe, envenomation is mostly due to Viperidae [13]. The incidence of European 
venomous Vipera spp bites is however difficult to assess. Mortality is low, but small children and 
elderly people may face life-threatening situations. Exotic snakes, including venomous species, are 
becoming increasingly popular pets in Western countries. Some of them are kept illegally. Exotic 
snake-handlers, including venomous species, and their physicians face a major challenge in Western 
countries [14]. Table 1 summarizes the geographic distribution of the most represented families of 
hemorrhagic venomous snakes. 
Table 1. Geographic distribution of hemorrhagic venomous snakes. 
Families of hemorrhagic venom snakes  Geographic distribution 
Elapidae  West Africa, South-East Asia, America, Australia 
and New Guinea. 
Colubridae  Worldwide except Antarctica, extremely high 
latitudes of Eurasia and North America and central 
and western Australia 
Crotalidae  Asia and America 
Viperidae  Europe, Africa, South-East Asia and USA 
2. Key Enzymes in Hemotoxic Venom Action 
Venoms from Viperidae, Crotalidae and some Australian snakes affect the hemostatic mechanism 
or  disrupt  the  endothelium  [13,14].  Their  venom  contains  serine-proteases,  hemorrhagins 
(fibrinogenases possessing high anti-thrombotic activity), fibrinolytic activators , metalloproteases and 
group II PLA2 isoenzymes, as well as non-enzymatic proteins (C-type lectins, CRISP and disintegrins) 
that activate or inhibit coagulant factors or platelets, or disrupt the endothelium [15]. To date, thanks to 
the  recent  developments  in  proteomic  techniques  and  mass  spectrometry  for  the  identification  of 
proteins, the snake venom proteome and the pharmacological properties of its components are being 
explored [16]. Many snake venom toxins affect platelet function by inducing or inhibiting platelet Toxins 2010, 2                        
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aggregation  [17].  Approximately  100  snake  venom  toxins  have  been  identified  as  ‗thrombin-like‘ 
enzymes activating the blood coagulation factor [18]. 
Neurotoxins are classified according to their site of action (i.e., pre- or post-synaptic). Post-synaptic 
neurotoxins are antagonists of the nicotinic receptor on the skeletal muscle leading to paralysis and 
eventually  death.  They  have  only  been  identified  in  venoms  from  the  families  Elapidae  and 
Hydrophiidae [18]. 
Phospholipase A2 (posphatidate 2-acylhydrolases, PLA2, EC 3.1.1.4). PLA2 are probably the most 
thoroughly investigated toxins both in hemotoxic and presynaptic neurotoxic snake venoms [19,20]. 
PLA2 has also been classified as a presynaptic neurotoxin, identified in the venoms of Crotalidae, 
Elapidae,  Hydrophiidae  and  Viperidae  snakes  [19].  PLA2  are  ubiquitous  intra-  and  extra-cellular 
enzymes hydrolyzing glycerophospholipids at the sn-2 position of the glycerol backbone releasing 
lysophospholipids and fatty acids [20], in turn arachidonate metabolites control inflammation and pain 
[21].  PLA2  are  responsible  for  the  local  inflammation  following  viperid  snakebite  envenomation. 
Venoms are rich sources of a large number of PLA2 isozymes [22], which can have pharmacological 
effects in vivo [23]. While mammalian PLA2 are generally nontoxic, snake venom enzymes or their 
complexes  are  the  active  component  of  both  hemotoxic  and  presynaptic  neurotoxic  venoms  of 
rattlesnakes  and  Australian  elapid  snakes  [22,24],  exhibiting  a  variety  of  pharmacological  effects, 
through mechanisms that can also be independent of its enzymatic activity [3,23]. 
For  hemotoxic  venoms,  conspicuous  toxic  consequence  of  snake  envenoming  is  hemorrhage 
production, which can become systemic and potentially lethal. Hemorrhages are principally caused by 
metalloproteases (also called hemorrhagins), enzymes degrading proteins of extracellular matrix and 
components of the hemostatic system, that can also have cytotoxic effect on endothelial cells [25,26]. 
The majority of metalloproteases belong to the family of zinc endopeptidases grouped together as a 
superfamily  known  as  zinc-dependent  Snake  Venom  Metallo  Proteinases  (SVMP,  also  called 
metzincins or hemorrhagins, EC 3.4.24.-). The metzincins are subdivided into four multigene families: 
seralysins, astacins, ADAMs/adamalysins, and MMPs. On the basis of sequence similarity they share a 
highly conserved motif containing three histidines [27] that bind to zinc at the catalytic site and a 
conserved  methionine  that  sits  beneath  the  active  site  [28].  Examples  are:  adamalysin  II  
(EC 3.4.24.46), atrolysin C/D (EC 3.4.24.42), trimerelysin I (EC 3.4.24.52) and II (EC 3.4.24.53) [29]. 
All  metalloproteases  contain  approximately  1 mole  of  zinc  per  mole  of  toxin  [27].  When  zinc  is 
removed from hemorrhagic toxins, for example with a chelator, proteolytic and hemorrhagic activities 
are simultaneously abolished due to structural alterations [30,31]. 
3. New and Old Approaches for Inhibition of Hemorrhagic Venoms 
Envenomations due to snake bites are commonly treated by parenteral administration of horse or 
sheep-derived  polyclonal  antivenoms  aimed  at  the  neutralization  of  toxins.  Although  there  is  no 
universal grading system for snakebites, a I through IV grading scale has been developed for clinical 
use, as a guide to antivenin administration. First-aid measures for snakebite include avoiding excessive 
activity, immobilizing the bitten extremity, and quickly transporting the victim to the nearest hospital. 
Venomous snakes, even dangerous ones like the Eastern diamondback, do not always release venom 
when they bite. US medical professionals may not agree on every aspect of what to do for snakebite Toxins 2010, 2                        
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first aid, but they agree on what not to do: no cooling, tourniquets, incisions and no electric shock on 
the bite, however the protocols for assistance of the victims of envenomation are money and time 
consuming.  
Developing  effective  and  cheap  antivenins  (sometimes  called  "antivenoms"),  designing  control 
assays, and recruiting the resources needed to validate them is an economic and ethic problem. Equine-
derived antivenin is considered the standard of care; however, snakebite victims who are sensitive to 
horse proteins must be carefully managed. They could in fact develop an adverse reaction or even an 
anaphylactic shock [12]. A sheep antibody preparation (CroFab) is now licensed for use in the United 
States [32] and is a promising new treatment. CroFab is sheep-derived antigen binding fragment ovine, 
which is much less allergenic, being digested to reduce the risk of allergic reactions. The venom of the 
snake  Bothrops  asper  has  been  the  subject  of  a  number  of  experimental  studies  addressing  its 
neutralization by antibodies. Recently, a process for raising antibodies against Bothrops sp venom in 
chicken egg yolks from hens immunized with Brazilian standard bothropic antigen preparation was 
developed in Brazil. The technique yielded antibodies capable of neutralizing lethal toxic activity of 
the pool of Bothrops venoms from five species [33].  
In the case of neurotoxic venoms, these cause little local tissue reaction, and the onset of the of 
clinical signs from neurotoxins (a curare like-syndrome) may be delayed for as much as 10 hours. 
Therefore,  the  treatment  is  exclusively  done  by  administration  of  specific  antivenins.  Antivenin 
development may not be affordable in many countries [8] and there are few lucrative markets for 
producers. This lack of competitive commerce reduces the incentives for progresses in the production 
of new antivenins. Moreover, the phenomenon of intraspecific variation in snake venom composition 
must be kept in mind. Because not all snakebites, including those from the same species, are equally 
dangerous,  doctors  sometimes  face  a  dilemma  over  whether  or  not  to  administer  antivenin  [32]. 
Despite the widespread success of antivenin therapy, it is still important to search for different venom 
inhibitors, either synthetic or natural, that could complement or substitute for the action of antivenins.  
3.1. Natural Venom Inhibitors 
Natural inhibitors of snake venoms play a significant role in the ability to neutralize the degradation 
effects induced by venom toxins. It has been known for many years that animal sera and some plant 
extracts  are  competent  in  neutralizing  snake  venoms.  Several  plants  have  been  utilized  in  folk 
medicine as antiophidians. However, only a few species have been scientifically investigated and still 
less have had their active components isolated and characterized both structurally and functionally. 
Protective  activity  of  many  of  these  plants  against  the  lethal  action  of  snake  venoms  has  been 
confirmed by biological assays. Compounds present in all of them belong to chemical classes capable 
of interacting with macromolecular targets (enzymes or receptors). Biotechnological application of 
these inhibitors, may represent helpful alternative or supplemental treatments to serum therapy [34]. 
Several substances have been evaluated regarding their effects against snake venoms and isolated 
venom toxins, including plant extracts and compounds from marine animals, mammals and snake 
serum plasma, in addition to many synthetic molecules [35]. 
Several Brazilian plants have been utilized in folk medicine as active agents against snake venoms. 
The aqueous extract of Pentaclethra macroloba (EPema) exhibited full inhibition of hemorrhagic and Toxins 2010, 2                        
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nucleolytic activities induced by several snake venoms. In vivo tests showed that EPema is able to 
inhibit a Bothrops jararacussu metalloprotease. Additionally, partial inhibition of PLA2s activities 
from snake venoms was reported. The mechanism of action of EPema is still unknown, but it seems 
that  proteolytic  degradation  as  a  potential  mechanism  can  be  excluded  [36].  The  aqueous  extract 
prepared  from  Schizolobium  parahyba  (Sp)  leaves,  a  native  plant  from  Atlantic  Forest  (Brazil), 
inhibited 100% of lethality, hemorrhagic and indirect hemolytic activities of Bothrops alternatus and 
Bothrops moojeni snake venoms. Together with tannins, the extract also contains other compounds that 
can display specific inhibitory activity against snake venom toxins [37]. An aqueous extract from the 
leaves of Casearia mariquitensis, a plant found in Brazilian open pastures, displays components able 
to inhibit some hematological and systemic alterations induced by neuwiedase, a 22 kDa class P-I 
metalloproteinase from the venom of the pit viper Bothrops neuwiedi pauloensis [38,39]. 
Natural and artificial inhibitors of enzymatic, toxic and pharmacological effects induced by snake 
venom PLA2s are known, which act on PLA2s through different mechanisms, most of them still not 
completely  understood.  These  include  binding  to  specific  domains,  denaturation,  modification  of 
specific amino acid residues and others. Naturally occurring anti-toxic factors that neutralize PLA2 
have been isolated from the blood of venomous snakes and studied [40–42]. Snake PLA2s inhibitors 
(PLIs) are large multimeric, serum proteins that form soluble complexes with PLA2 enzymes, thereby 
inhibiting their actions. The first PLIs were isolated from the serum of Habu snake, Trimeresurus 
flavoviridis (Protobothrops flavoviridis; EMBL Reptile Database) [43]. PLIs show specific affinities 
for  various  PLA2  enzymes  and  some  have  been  shown  to  have  anti-enzymatic,  anti-myotoxic,  
anti-edema-inducing, anti-cytotoxic and anti-bacterial activities [44]. Fractionation of the serum of the 
venomous snake Bothrops jararaca resulted in the isolation of the anti-hemorrhagic factor BJ46a. 
BJ46a is a potent inhibitor of the SVMPs atrolysin-C (class P-I) and jararhagin (P-III) proteolytic 
activities and B. jararaca venom hemorrhagic activity. That was the first report of a complete cDNA 
sequence for an endogenous inhibitor of snake venom SVMPs.  
Recent studies on the functional basis of venom resistance show that blood serum from California 
ground squirrels can reduce the hemolytic activity of rattlesnake venom, as well as the activity of 
venom metalloproteases and other enzymatic toxins [45]. California ground squirrels were found to 
possess blood proteins that work as SVMP Inhibitors (SVMPIs). Those proteins are also present in the 
Ig Supergene family, but are not the same as SVMPIs from other species of mammals that are resistant 
to rattlesnake venom.  
3.2. Electric Current Treatment 
In the late 1980s, a different approach was attempted to treat snake-bite injuries. Local application 
of high-voltage low-amperage direct electric current (dc) (so-called ―electric shock for snakebites‖) 
was reported by Guderian et al. [46] to be successful with 34 venomous snakebite injuries treated in 
the Amazon Jungle of Ecuador (where at the time poisonous snakebites were responsible for 4% of 
deaths). The treatment involved local application of a high voltage (20–25 kV) low amperage (<1 mA) 
dc for 1–2 s around the bite, from a portable system (―Stun-gun‖) they had developed. The report 
claimed that 10 min after treatment, pain had gone and the sequelae of untreated bites (swelling, 
hemorragia, shock and renal failure, intense pain, edema, weakness, rapid pulse, bleeding disorders) Toxins 2010, 2                        
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did not develop [46]. A local effect or a direct effect on venom itself was proposed. A good experience 
with ―Nova Spirit‖, a Stun-gun, on a rattlesnake bite was reported [47]. Kroegel and Meyer zum 
Bü shenfelde [48] speculated that electric shocks would influence the hydrogen bonds and metal ions of 
the  venom  enzymes,  and  reported  a  decrease  in  the  histamine  releasing  activity  of  melittin  after 
exposure of bee venom to high-voltage, but the biological basis for the treatment remains unknown. In 
field experiments with a so-called ―Stun-gun‖, it was reported that ―all pain had gone‖ from the bitten 
limb [46].  
Nowadays, a similar patent-pending device (ECOBITE, G. C. C., Switzerland) is commercialized in 
the USA and Europe for high-voltage electric low-amperage shock treatment of various poisonous 
bites (from insects, arthropods, and vertebrates), but its use is not recommended due to a lack of 
scientific basis [49]. Prevention is far preferable. Nevertheless, in many countries the serious problems 
posed by life-threatening venomous bites is a reality.  
Indeed, dc is largely employed in medical practice by a number of diverse empirical devices for 
treatment of inflammation and pain. For example, the Transcutaneous-Electrical-Stimulation (TENS) 
is an electronic device that produces electrical currents by connecting two or more electrodes to the 
skin [50]. TENS and other devices are empirical devices that seem to get good results, even though 
they  still  need  a  scientific  validation.  A  recent  report  would  offer  a  first  scientific  basis  for  the 
understanding of the mode of action  of dc on enzymes [51].  In  fact, the study of the interaction 
between dc and proteins is a poorly explored topic. When low (instead of high) voltages (0-10 V) were 
employed  to  expose  reconstituted  Crotalus  atrox  (Western  Diamondback  rattlesnake)  venom  in 
solution to dc (0-0.7 mA), it was found that after 1-5 seconds of exposure three of the most potent 
hemotoxic venom enzymes i.e., Phosphatidate 2-acylhydrolase (phospholipase A2, PLA2, EC 3.1.1.4), 
phosphodiesterases  (oligonucleate  5‘-nucleotido  hydrolase,  exonuclease  I,  PDE,  EC  3.1.4.1),  and 
SVMPs,  were  irreversibly  inactivated  (>80%)  [52].  As  for  what  metalloproteinase  inhibition  is 
concerned, it was hypothesized that inactivation of C. atrox venom metalloproteases by dc application 
is  due  to  displacement  or  removal  the  Zn
2+  ion  from  the  enzyme  active  site,  causing  enzyme 
inactivation [52]. Chelation of the zinc atom by other means was reported to abolish both proteolytic 
and hemorrhagic effects of the venom [30].This would be consistent with the report from Kroegel and 
Meyer zum Bü shenfelde [48], who supposed that electric current may influence metal ion moieties of 
some  venom  enzymes.  Also,  in  field  treatments  with  ―stun  gun‖  Guderian  reported  that  ‖the 
hemorrhagic sequelae of untreated poisonous bites were ruled out‖ [46]. 
Metal chelation can be accomplished in many ways: by treatment at low pH, or with chelating 
agents. For example, the lethal toxicity, of an hemorrhagic fibrinogenase toxin f (HT-f) isolated from 
Crotalus atrox venom containing 1 mol of zinc per mol of protein, was lost upon removal of Zn
2+ from 
the  apo-HT-f,  by  treatment  at  low  pH  values  or  with  chelating  agents  [31].  Acurhagin,  a 
metalloproteinase  from  Agkistrodon  acutus  venom,  was  completely  inactivated  by  treatment  with 
metal  chelators  [53].  Citrate  (100  mM)  was  found  to  inhibit  Crotalus  adamanteus  venom 
metalloproteases and phosphodiesterases also in vivo [54]. PLA2 and metalloproteases with disintegrin 
domains  are  among  the  major  venomous  enzymatic  components  of  hemotoxic  Viperidae  snake  
venoms [55]. 
For what the inhibition of Crotalux atrox PLA2 by dc exposure is concerned, the parameter CH-PO 
(CHarged  minus  POlar  amino  acids,  i.e.,  the  percentage  of  charged  residues  subtracted  from  the Toxins 2010, 2                        
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percentage of polar residues of a protein [56]) seems to be related to the electro-inactivation of this 
protein [51]. Interestingly, many enzymes from venoms of various animals display a high CH-PO. 
venom PLA2 is one of these (CH-PO value: 12). A recent study reports that enzymes with CH-PO 
higher than 10.0 were irreversibly inactivated by dc; while those with CH-PO between +3 and –5 were 
not (CH-PO threshold at 10.0) [51]. Circular Dichroic spectroscopy showed a loss in ordered structure 
after PLA2 exposure to dc [49]. Therefore, it seems that a crucial role is played by dc in determining 
venom enzyme inactivation [51,52]. The  topic  of the treatment of venomous  snake-bites  by local 
application  of  low-voltage  low-amperage  electric  current,  may  become  clinically  interesting  for 
treatment  of  snake  bites  for  both  humans  and  animals  (for  example  hunting  dogs).  Interestingly, 
ammodytoxin,  a  PLA2  from  the  venom  of  Vipera  ammodytes  ammodytes  is  a  potent  presynaptic 
neurotoxin [57]. It is tempting to speculate that the treatment with dc through the skin reported by 
Guderian et al. [44] had inactivated venom PLA2 [21]. 
Many thermostable proteins display a large difference between charged (Asp, Glu, Lys, Arg) versus 
polar (Asn,
 Gln, Ser, Thr) amino acids [56], and therefore a high CH-PO value. A network of ion 
bonds at the protein surface stabilizes many thermostable proteins, while the number of polar residues 
(tending to introduce the aqueous solvent into the core of the protein) is low [58]. Anyway, other 
factors contribute toward thermal stability of (i.e., increase in secondary structure, in hydrophobic 
interactions, disulfide bonds and oligomerization) [59].  
The advantages and disadvantages of the different ways to inhibit the hemorrhagic venoms are 
reviewed in Table 2. 
More rigorous physical-chemical studies are needed for the interpretation of the interaction between 
dc and proteins at the molecular level. In turn, the research on the possible applications of compounds 
form plants of animals, capable of inhibit macromolecular components of snake venoms may supply 
helpful alternative or supplemental treatments to serum therapy. Undoubtedly, the perspective of the 
availability of affordable, inoffensive means to inactivate snake venoms in vivo is quite attractive. 
Table 2. Advantages and disadvantages of different approaches to inhibit hemorrhagic venoms. 
Approach for inhibition of 
hemorrhagic venom 
Advantages  Disadvantages 
Horse or sheep-derived polyclonal 
antivenins 
Large-scale use 
High efficacy  
Adverse reaction or anaphylactic shock 
Economic and ethic problems 
Sheep-derived antibody (CroFab)  Utilized 
High efficacy  
Less allergenic 
Economic and ethic problems 
Polyclonal antibodies purified from 
chicken egg yolks of immunized hens 
(developed for Bothrops sp. venoms) 
Promising for the yield of 
antibody 
Probably less allergenic 
Economic problems 
Not utilized  
(protocols to be developed and efficacy 
tested)  
Natural inhibitors  Probably less allergenic  Economic problems 
Not utilized (protocols to be developed) 
Electric current treatment  Probably not allergenic  
Applicable by a portable system 
Not utilized nor recommended  
(lack of scientific basis) Toxins 2010, 2                        
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